Glofil-125

Sodium Iothalamate I-125 Injection


Iso-tex Diagnostics, Inc.
Human Prescription Drug
NDC 50914-7729
Glofil-125 also known as Sodium Iothalamate I-125 Injection is a human prescription drug labeled by 'Iso-tex Diagnostics, Inc.'. National Drug Code (NDC) number for Glofil-125 is 50914-7729. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Glofil-125 drug includes Iothalamate Sodium I-125 - .275 mCi/mL . The currest status of Glofil-125 drug is Active.

Drug Information:

Drug NDC: 50914-7729
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Glofil-125
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Iothalamate I-125 Injection
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Iso-tex Diagnostics, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:IOTHALAMATE SODIUM I-125 - .275 mCi/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 May, 1983
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 17 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA017279
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Iso-Tex Diagnostics, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0050914772920
UPC stands for Universal Product Code.
UNII:31J5U3Q9ZN
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Radioactive Diagnostic Agent [EPC]
Radiopharmaceutical Activity [MoA]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
50914-7729-21 VIAL, MULTI-DOSE in 1 BOX (50914-7729-2) / 4 mL in 1 VIAL, MULTI-DOSE01 May, 1983N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Glofil-125 sodium iothalamate i-125 injection iothalamate sodium i-125 iothalamic acid i-125 benzyl alcohol sodium bicarbonate hydrochloric acid

Indications and Usage:

Indications and usage glofil-125 (sodium iothalamate i-125 injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.

Warnings:

Warnings none known

Dosage and Administration:

Dosage the suggested dose range employed in the average patient (70 kg) is as follows: continuous intravenous infusion: 20 to 100 μci (0.74-3.7 megabecquerels) (sigman, et al (1) method). single intravenous injection: 10 to 30 µci (0.37-1.11 megabecquerels) cohen, et al (2) method) the patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. technique continuous intravenous infusion sigman 1 method i. preparation: adequate diuresis (a urine flow exceeding 3 ml/min.) is established, preferably by an oral water load of 1,500 ml two hours prior to the beginning of the clearance study. 2. it is not necessary to withhold breakfast or admit the patient the night before. ii. procedure: after the establishment of adequate diuresis, a number 14 or 16 french foley catheter is aseptically inserted into the bladder. an intravenous infusion of lactated ringers (hartmanns) solution is started in each arm, one to maintain a site for inj
ection of the glofil-125, the other to serve as a site for serial withdrawal of blood. a two-way stopcock connects the needle and intravenous tubing of each arm. the dose is equally divided into (1) an intravenous priming dose to be injected as is and (2) a sustaining dose to be diluted in 30 to 60 ml of isotonic sodium chloride, depending on how many collection periods are anticipated. the priming dose is slowly injected into one arm. this is immediately followed by infusion of the sustaining solution through the same site, usually at the rate of 0.5 ml/min., by means of an automatic pump. during this infusion, the lactated ringers solution in the same arm is discontinued, and 40 to 45 minutes are allowed for equilibration in order to reach a state of constant plasma concentration of radioactivity. after attaining equilibrium, consecutive 15 minute collection periods are started. from the arm opposite the injection site, 5 ml of blood (allowing duplicate plasma counting volumes) is drawn six minutes prior to the midpoint of each collection period, placed in heparinized tubes, mixed, and centrifuged. the blood samples may be obtained through the two-way stopcock after discarding the first 30 ml aspirated into the syringe. this 30 ml contains the contents of the tubing, including infusion fluid, and must be cleared in order to obtain an undiluted blood sample. if desired, this step may be eliminated and blood samples obtained by direct venipuncture. during each collection period, total urine must be accurately collected and the volume accurately measured. three such consecutive collection periods are sufficient for most clinical studies. iii. clearance calculations: 1. aliquots (1 ml each) of plasma and urine from each collection period are counted in a standard gamma-ray scintillation well detector. 2. all counts are corrected for background activity. 3. glomerular filtration rate is calculated by the formula c=uv/p, in which: c = glomerular filtration rate in ml/min u= urinary concentration of radioactivity in net counts/min/ml v= urinary flow rate in ml/min p = plasma concentration of radioactivity in net counts/min/ml 4. average glomerular filtration rate (gfr) is calculated from the rates for the individual collection periods. gfr can be expressed in terms of body weight (ml/min/kg) or body surface area (ml/min/m 2 ). 5. unilateral glomerular filtration rates can be determined by the same technique by utilizing ureteral catheterization. single intravenous injection cohen 2 method: the method of cohen, et al 2 requires little preparation, few and small blood samples, no bladder catheterization, and no constant intravenous infusion. it is simple to perform, rapid, and utilizes equipment which is readily available in most modern laboratories. i. preparation: 1. lugol's solution, 3 drops orally, three times a day, is administered for one or two days prior to the test. no diet or water restriction is necessary. 2. oral water load is begun one hour before starting the test. start with 20 ml/kg and force any clear liquids (unless contraindicated) until the test is complete. ii. procedure: record actual times for the collection of the blood and urine samples. 1. empty the bladder and label the urine urine control. 2. inject 10-30 µci glofil-125 intravenously; wait 30 to 60 minutes. 3. collect the entire urine and label urine discard. 4. draw 4 to 5 ml of blood into a heparinized syringe. label plasma #1. 5. after another 30 to 60 minutes, collect the entire urine and label urine #1. 6. immediately draw another blood specimen. label plasma #2. 7. after final 30 to 60 minute wait, collect the urine. label urine #2. 8. draw the last blood specimen immediately. label plasma #3. iii. clearance calculations: 1. radioactivity of one ml aliquots of both urine and plasma are determined using a well-scintillation detector with a single channel pulse-height analyzer. sufficiently reproducible counts are usually obtained with time settings of 2 minutes for urine samples and 20 minutes for the plasma samples. calculations of the clearance rates are made by using the formula:(1) c = c = uv/p + 1.73/sa where c = glomerular filtration rate in ml/min/1.73 m 2 u = urine radioactivity in counts/min/ml v = urine flow rate in ml/min p= mean plasma radioactivity in counts/min/ml sa= body surface area in m 2 radiation dosimetry the estimated absorbed radiation doses to an average (70 kg) patient from an intravenous dose of 100 µci (3.7 megabecquerels) of glofil-125 are shown in table 4. calculations assume that there is 1% free iodide in the preparation and that the thyroid uptake of the iodine is 25%. image description

Contraindications:

Contraindications glofil-125 should not be administered via a central venous line.

Adverse Reactions:

Adverse reactions none reported

Description:

Description general glofil-125 (sodium iothalamate i-125 injection) is a sterile, nonpyrogenic aqueous injection containing approximately 1 mg sodium iothalamate per ml, and 0.9 percent benzyl alcohol as a preservative. the radioactive concentration of the material is 250-300 µci/ml as of the calibration date. sodium bicarbonate and hydrochloric acid are present for ph adjustment.

Clinical Pharmacology:

Clinical pharmacology the renal clearance of sodium iothalamate in man closely approximates that of inulin. the compound is cleared by glomerular filtration without tubular secretion or reabsorption. following infusion administration of i-125 iothalamate, the effective half-life is about 0.07 days.

How Supplied:

How supplied identity no. 1000, glofil-125 is a clear, colorless, sterile, and nonpyrogenic solution available as a 4 ml vial. it is supplied in a concentration of approximately 1 mg/ml sodium iothalamate (range is 0.5–2.0 mg sodium iothalamate per ml), with a radioactivity concentration of 250 to 300 μci/ml at the time of calibration. benzyl alcohol 0.9%, is added as a preservative. sodium bicarbonate and hydrochloric acid are added for ph adjustment. the calibration and expiration dates are shown on the label.

Package Label Principal Display Panel:

Packaging image description


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.